{"entity":{"id":"ctdna-monitoring-lead-time","kind":"term","name":"Lead time in ctDNA monitoring studies","aka":["ctDNA lead time","molecular lead time"],"tldr":"Lead time is the measured gap between a first qualifying positive blood sample and a later clinical event. It depends on who is counted and when tests were done, and it is not extra life.","summary":"In a ctDNA monitoring study, lead time is the date of a defined later event, such as confirmed clinical recurrence, minus the date of the first qualifying positive blood sample. The definition needs rules: whether recurrence means imaging, pathology or symptoms, whether the blood date is collection or reporting, whether a positive result triggered an extra scan, and whether treatment began on the signal. Blood draws and scans are both intermittent, so the observed gap reflects both schedules. A negative draw at month 3 and a first positive at month 6 do not locate when the signal began.\n\nThe denominator matters as much as the number. A median taken only over people with both an earlier positive and a later recurrence describes that selected group. It leaves out recurrences with no earlier positive, and people who are positive but have not recurred at the data cutoff have unfinished intervals, which are censored rather than zero or infinite. In García-Murillas and colleagues' prospective breast-cancer study, with blood taken every 3 months in the first year and every 6 months after, ctDNA detection preceded clinical relapse by a median of 10.7 months (95% CI 8.1 to 19.1) in the combined cohort of 144, and ctDNA found distant extracranial relapse in 22 of 23 patients but brain-only relapse in 1 of 6. In the c-TRAK TN trial, ctDNA was detected in 27.3% by 12 months and 7 patients relapsed without prior detection. A longer lead time shows earlier detection. It does not show that acting on the signal helps people live longer, which is the separate lead-time bias problem.","asOf":"2026-11-10","wikipedia":"https://en.wikipedia.org/wiki/Lead_time_bias","links":[{"label":"García-Murillas et al., JAMA Oncol 2019: molecular relapse detection in early-stage breast cancer","url":"https://doi.org/10.1001/jamaoncol.2019.1838"},{"label":"Turner et al., Ann Oncol 2023: c-TRAK TN, ctDNA surveillance in triple-negative breast cancer","url":"https://doi.org/10.1016/j.annonc.2022.11.005"},{"label":"FDA, Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development, November 2024","url":"https://www.fda.gov/media/183874/download"}],"tags":["biomarker","measurement","evidence"],"related":["lead-time-bias","ctdna","mrd","continuous-ctdna-monitoring","mrd-testing"],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["ctdna","mrd","lead-time-bias"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023"],"journals":[],"dependsOn":[],"notes":["Method card, what it measures: the difference between two prespecified event dates after the assay's qualifying rule, in days or months, with the number of evaluable people, the distribution and its uncertainty. It needs serial blood tests and clinical follow-up, and a draw schedule is part of the result.","Table, thresholds and rules: the positive and confirmation criteria for the blood test, the definition of the clinical event, and which date counts for each. Failure modes are missing visits, scans triggered by a positive result, selection into the group, short follow-up and a course changed by intervention.","Table, what it cannot tell: added survival, a personal recurrence date, the biological onset of disease, or a ranking of assays. Medians from different cohorts, sites of recurrence, draw schedules and confirmation rules are not comparable with one another.","Fictional arithmetic: six people recur at month 12 and are drawn every 2 months. A to D have first positives giving gaps of 2, 4, 6 and 8 months. E and F have no earlier positive. The median of 2, 4, 6 and 8 is (4 + 6) / 2 = 5 months among four people. It leaves out E and F, so it is not a statement that every recurrence was found 5 months early, and the two detection failures are reported alongside it.","For the fictional completed-interval example above, the median is conditional on having both an earlier positive and a later event. People with no prior positive are detection failures for that surveillance question, rather than zero-month observations added to that selected median. People positive without a later event have unfinished follow-up; a time-to-event estimator can handle censoring under its stated assumptions. The estimator and the people included must be named.","Interpretation rule, from intermittent sampling: because the first positive can only fall on a draw date, the gap begins at an observed sample and cannot locate when the signal first became detectable. The same holds for the end of the gap when scans are also periodic.","Evidence read, García-Murillas 2019: 170 women recruited and 101 in the main cohort with mutations identified, tracked by tumour-specific digital PCR in plasma every 3 months in the first year and every 6 months after. In the main cohort, detection during follow-up was associated with relapse (hazard ratio 25.2, 95% CI 6.7 to 95.6). In the combined cohort of 144, median lead time over clinical relapse was 10.7 months. This is an association in one assay and population.","Evidence read, c-TRAK TN: 161 patients entered three-monthly ctDNA surveillance by digital PCR; detection by 12 months was 27.3% (44 of 161). Seven patients relapsed without prior detection. Among those allocated to the intervention, 72% (23 of 32) already had metastases on staging at the time of ctDNA positivity, and of 5 who started pembrolizumab none had sustained clearance, so in this small group the earlier signal was not followed by a measured benefit.","State how lead time was estimated. A simple median of completed positive-to-recurrence intervals is conditional on that selected group; a time-to-event analysis can also incorporate censored follow-up. People without a prior positive and people positive without a later recurrence therefore need explicit dispositions under the study definition. They are not automatically zero-month, infinite or missing intervals interchangeable across studies.","For the García-Murillas estimate, 144 is the combined cohort size, not a count of completed lead-time intervals. The Results report 29 patients with molecular residual disease. The report's cohort size does not establish how many intervals entered the lead-time estimate; that analysis denominator remains unverified here. The observed detection rate, sites of missed recurrence and handling of censored follow-up must accompany interpretation of the median.","The interval available for action can be shorter than the collection-to-recurrence gap because laboratory reporting takes time. Missing draws, assay failures, exclusions, deaths or other competing events, and intervention after a positive result need explicit dispositions. Prespecifying the schedule and event rules, reporting the evaluable denominator and uncertainty, and describing whether results were blinded to the clinical team and whether a positive result triggered extra imaging help make the result interpretable. Earlier detection and improved survival remain different outcomes."],"category":"Biomarkers"},"route":"/terms/ctdna-monitoring-lead-time/","neighbours":{"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"technology":[{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"paper":[{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/"},{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/"}]}}